Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.785
-0.025 (-1.38%)
May 28, 2026, 12:54 PM EDT - Market open
Cardiff Oncology Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Cardiff Oncology stock has a consensus rating of "Strong Buy" and an average price target of $7.69. The average 1-year stock price forecast is 330.81% higher than the current stock price, while the lowest is $2.00 (+12.04%) and the highest is $12 (+572.27%).
Price Target: $7.69 (+330.81%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cardiff Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Noble Financial | Noble Financial | Buy Reiterates $12 | Buy | Reiterates | $12 | +572.27% | May 22, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $6 | Buy | Reiterates | $6 | +236.13% | May 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 | Buy | Reiterates | $10 | +460.22% | May 15, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 15, 2026 |
Financial Forecast
Revenue This Year
354.82K
from 593.00K
Decreased by -40.17%
Revenue Next Year
193.08K
from 354.82K
Decreased by -45.58%
EPS This Year
-0.61
from -0.69
EPS Next Year
-0.79
from -0.61
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 729,750 | 761,250 | ||||||
| Avg | 354,817 | 193,076 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 23.1% | 114.5% | ||||||
| Avg | -40.2% | -45.6% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.39 | -0.58 | ||||||
| Avg | -0.61 | -0.79 | ||||||
| Low | -0.80 | -1.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.